ClinicaliQ Trial Snapshot
- A Long-Term Safety and Efficacy Study of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALOUR) — Active Not Recruiting • Phase II • Respiratory / COPD / Asthma • NCT06966479.
- Review the linked registry entry for study design, population, endpoints, and operational status.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The primary purpose of this study is to evaluate the long-term safety and efficacy of verekitug (UPB-101) in participants who complete the VALIANT study (NCT06196879). Conditions: Severe Asthma Interventions: Verekitug, Placebo Lead Sponsor: Upstream Bio Inc. Planned Enrollment: 396 participants